Synapse - Works

Results (2639)

The 23-gene gene expression-based assay does not predict interim PET scan results after ABVD in advanced stage classical Hodgkin lymphoma in the US Intergroup S0816 trial

Meeting Abstract

Scott, D. W.; Li, H.; Harvey, Y.; Chan, F.; Mottok, A.; Boyle, M.; Evens, A. M.; Schoder, H.; Straus, D. J.; Bartlett, N. L.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Risk-adapted therapy in adults with Burkitt lymphoma: Updated results of a multicenter prospective Phase II study of DA-EPOCH-R

Meeting Abstract

Dunleavy, K.; Roschewski, M.; Abramson, J. S.; Link, B.; Parekh, S.; Jagadeesh, D.; Bierman, P.; Watson, P. R.; Peace, D.; Hanna, W.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Interim results from a Phase 1/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Herrera, A. F.; Moskowitz, A. J.; Bartlett, N. L.; Vose, J. M.; Ramchandren, R.; Feldman, T. A.; Lacasce, A. S.; Ansell, S. M.; Moskowitz, C. H.; Fenton, K.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Phase I/IB dose escalation and expansion of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma

Meeting Abstract

Batlevi, C.; Hamlin, P.; Matasar, M.; Gerecitano, J.; Drullinsky, P.; Hamilton, A.; Straus, D.; Horwitz, S.; Kumar, A.; Moskowitz, C.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Improved survival outcomes for patients with extra-nodal NK/T lymphoma: Data from 140 patients prospectively registered in the international T-cell project

Meeting Abstract

Fox, C. P.; Bellei, M.; Manni, M.; Kim, S. J.; Ko, Y. H.; Shustov, A. R.; Cabrera, M. E.; Chiattone, C. S.; Horwitz, S. M.; Spina, M.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Brentuximab vedotin vs physician's choice in CTCL patients from the Phase 3 ALCANZA study: Analysis of outcomes by CD30 expression

Meeting Abstract

Kim, Y. H.; Prince, H. M.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Bechter, O.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a Phase 2 study in patients with relapsed/refractory B-cell malignancies

Meeting Abstract

Hamlin, P. A.; Farber, C. M.; Fenske, T. S.; Khatcheressian, J. L.; Miller, C. B.; Munoz, J.; Patel, M. R.; Schreeder, M. T.; Smith, S. M.; Stevens, D. A.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Chronic lymphocytic leukemia: Individualizing treatment approach

Journal Article

Zelenetz, A. D.
Journal of the National Comprehensive Cancer Network (2017)

Fulltext@MSK | Save

The landscape of new drugs in lymphoma

Journal Article

Younes, A.; Ansell, S.; Fowler, N.; Wilson, W.; De Vos, S.; Seymour, J.; Advani, R.; Forero, A.; Morschhauser, F.; Kersten, M. J.; more...
Nature Reviews Clinical Oncology (2017)

Fulltext@MSK | Save